[1]
|
Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., et al. (2021) Hepatocellular Carcino-ma. Nature Reviews Disease Primers, 7, Article No. 6. https://doi.org/10.1038/s41572-020-00240-3
|
[2]
|
Roayaie, S., Obeidat, K., Sposito, C., Mariani, L., Bhoori, S., Pellegrinelli, A., et al. (2013) Resection of Hepatocellular Cancer ≤ 2cm: Results from Two Western Centers. Hepatology, 57, 1426-1435. https://doi.org/10.1002/hep.25832
|
[3]
|
Zhu, A.X., Finn, R.S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., et al. (2018) Pembrolizumab in Patients with Ad-vanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open- La-bel Phase 2 Trial. The Lancet Oncology, 19, 940-952.
|
[4]
|
El-Khoueiry, A.B., Sangro, B., Yau, T., Crocenzi, T.S., Kudo, M., Hsu, C., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. https://doi.org/10.1016/S0140-6736(17)31046-2
|
[5]
|
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R. and Mantovani, A. (2020) Neutrophil Diversity and Plasticity in Tumour Progression and Therapy. Nature Reviews Cancer, 20, 485-503.
https://doi.org/10.1038/s41568-020-0281-y
|
[6]
|
Jensen, H.K., Donskov, F., Marcussen, N., Nordsmark, M., Lundbeck, F. and von der Maase, H. (2009) Presence of Intratumoral Neutrophils Is an Independent Prognostic Factor in Localized Renal Cell Carcinoma. Journal of Clinical Oncology, 27, 4709-4717. https://doi.org/10.1200/JCO.2008.18.9498
|
[7]
|
Grenader, T., Nash, S., Adams, R., Kaplan, R., Fisher, D., Maughan, T., et al. (2016) Derived Neutrophil Lymphocyte Ratio Is Predictive of Survival from Intermittent Therapy in Advanced Colorectal Cancer: A Post Hoc Analysis of the MRC COIN Study. British Journal of Cancer, 114, 612-615. https://doi.org/10.1038/bjc.2016.23
|
[8]
|
Gu, X., Gao, X., Li, X., Qi, X., Ma, M., Qin, S., et al. (2016) Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: Evidence from 16, 266 Patients. Scientific Reports, 6, Article No. 22089.
https://doi.org/10.1038/srep22089
|
[9]
|
Lin, G., Liu, Y., Li, S., Mao, Y., Wang, J., Shuang, Z., et al. (2016) Ele-vated Neutrophil-to-Lymphocyte Ratio Is an Independent Poor Prognostic Factor in Patients with Intrahepatic Cholangi-ocarcinoma. Oncotarget, 7, 50963-50971.
https://doi.org/10.18632/oncotarget.7680
|
[10]
|
Sun, H.L., Pan, Y.Q., He, B.S., Nie, Z.L., Lin, K., Peng, H.X., et al. (2016) Prognostic Performance of Lymphocyte-to-Monocyte Ratio in Diffuse Large B-Cell Lymphoma: An Updated Meta-Analysis of Eleven Reports. OncoTargets and Therapy, 9, 3017-3023. https://doi.org/10.2147/OTT.S96910
|
[11]
|
Diem, S., Schmid, S., Krapf, M., Flatz, L., Born, D., Jochum, W., et al. (2017) Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers in Pa-tients with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab. Lung Cancer, 111, 176-181. https://doi.org/10.1016/j.lungcan.2017.07.024
|
[12]
|
Guo, L., Ren, H., Pu, L., Zhu, X., Liu, Y. and Ma, X. (2020) The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study. Cancer Management and Research, 12, 7173-7188. https://doi.org/10.2147/CMAR.S257934
|
[13]
|
Sangro, B., Melero, I., Wadhawan, S., Finn, R.S., Abou-Alfa, G.K., Cheng, A.L., et al. (2020) Association of Inflammatory Biomarkers with Clinical Outcomes in Nivolumab-Treated Pa-tients with Advanced Hepatocellular Carcinoma. Journal of Hepatology, 73, 1460-1469. https://doi.org/10.1016/j.jhep.2020.07.026
|
[14]
|
Choi, W.M., Kim, J.Y., Choi, J., Lee, D., Shim, J.H., Lim, Y.S., et al. (2021) Kinetics of the Neutrophil-Lymphocyte Ratio during PD-1 Inhibition as a Prognostic Factor in Advanced Hepatocellular Carcinoma. Liver International, 41, 2189-2199. https://doi.org/10.1111/liv.14932
|
[15]
|
Muhammed, A., Fulgenzi, C.A.M., Dharmapuri, S., Pinter, M., Balcar, L., Scheiner, B., et al. (2021) The Systemic Inflammatory Re-sponse Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers, 14, Article 186. https://doi.org/10.3390/cancers14010186
|
[16]
|
Waugh, D.J. and Wilson, C. (2008) The Interleu-kin-8 Pathway in Cancer. Clinical Cancer Research, 14, 6735-6741.
https://doi.org/10.1158/1078-0432.CCR-07-4843
|
[17]
|
Motomura, T., Shirabe, K., Mano, Y., Muto, J., Toshima, T., Umemoto, Y., et al. (2013) Neutrophil-Lymphocyte Ratio Reflects Hepatocellular Carcinoma Recurrence after Liver Transplantation via Inflammatory Microenvironment. Journal of Hepatology, 58, 58-64. https://doi.org/10.1016/j.jhep.2012.08.017
|
[18]
|
Calderaro, J., Couchy, G., Imbeaud, S., Amaddeo, G., Letouzé, E., Blanc, J.F., et al. (2017) Histological Subtypes of Hepatocellular Carcinoma Are Related to Gene Mutations and Molec-ular Tumour Classification. Journal of Hepatology, 67, 727-738. https://doi.org/10.1016/j.jhep.2017.05.014
|
[19]
|
Chan, S.L., Mo, F.K., Johnson, P.J., Hui, E.P., Ma, B.B., Ho, W.M., et al. (2009) New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients with Hepatocellular Carcinoma Undergoing Systemic Chemotherapy. Journal of Clinical On-cology, 27, 446-452.
https://doi.org/10.1200/JCO.2008.18.8151
|
[20]
|
Vora, S.R., Zheng, H., Stadler, Z.K., Fuchs, C.S. and Zhu, A.X. (2009) Serum α-Fetoprotein Response as a Surrogate for Clinical Outcome in Patients Receiving Systemic Therapy for Advanced Hepatocellular Carcinoma. Oncologist, 14, 717-725. https://doi.org/10.1634/theoncologist.2009-0038
|
[21]
|
Shao, Y.Y., Lin, Z.Z., Hsu, C., Shen, Y.C., Hsu, C.H. and Cheng, A.L. (2010) Early α-Fetoprotein Response Predicts Treatment Efficacy of Antiangiogenic Systemic Therapy in Patients with Advanced Hepatocellular Carcinoma. Cancer, 116, 4590-4596. https://doi.org/10.1002/cncr.25257
|
[22]
|
Hu, X., Chen, R., Wei, Q. and Xu, X. (2022) The Landscape of α Feto-protein in Hepatocellular Carcinoma: Where Are We? International Journal of Biological Sciences, 18, 536-551. https://doi.org/10.7150/ijbs.64537
|
[23]
|
Spahn, S., Roessler, D., Pompilia, R., Gabernet, G., Gladstone, B.P., Horger, M., et al. (2020) Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers, 12, Article 3830. https://doi.org/10.3390/cancers12123830
|
[24]
|
Scheiner, B., Pomej, K., Kirstein, M.M., Hucke, F., Finkelmeier, F., Waidmann, O., et al. (2022) Prognosis of Patients with Hepatocellular Carcinoma Treated with Immunothera-py—Development and Validation of the CRAFITY Score. Journal of Hepatology, 76, 353-363. https://doi.org/10.1016/j.jhep.2021.09.035
|
[25]
|
Yang, Y., Ouyang, J., Zhou, Y., Zhou, J. and Zhao, H. (2022) The CRAFITY Score: A Promising Prognostic Predictor for Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitor and Immunotherapy Combinations. Journal of Hepatology, 77, 574-576. https://doi.org/10.1016/j.jhep.2022.03.018
|
[26]
|
Chen, J., Zaidi, S., Rao, S., Chen, J.S., Phan, L., Farci, P., et al. (2018) Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expres-sion Changes in the Transforming Growth Factor-β Pathway. Gastroenterology, 154, 195-210. https://doi.org/10.1053/j.gastro.2017.09.007
|
[27]
|
Chen, J., Gingold, J.A. and Su, X. (2019) Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma. Trends in Molecular Medicine, 25, 1010-1023. https://doi.org/10.1016/j.molmed.2019.06.007
|
[28]
|
Rebouissou, S. and Nault, J.C. (2020) Advances in Molecular Classification and Precision Oncology in Hepatocellular Carcinoma. Journal of Hepatology, 72, 215-229. https://doi.org/10.1016/j.jhep.2019.08.017
|
[29]
|
Park, B.V., Freeman, Z.T., Ghasemzadeh, A., Chattergoon, M.A., Rutebemberwa, A., Steigner, J., et al. (2016) TGFβ1- Mediated SMAD3 Enhances PD-1 Expression on Anti-gen-Specific T Cells in Cancer. Cancer Discovery, 6, 1366-1381.
https://doi.org/10.1158/2159-8290.CD-15-1347
|
[30]
|
Chen, J. and Su, X. (2020) Abstract 4286: TGF-β Signature Is a Therapeutic Biomarker for Combination Immunotherapy for Hepatocellular Carcinoma. Cancer Research, 80, 4286. https://doi.org/10.1158/1538-7445.AM2020-4286
|
[31]
|
Feun, L.G., Li, Y.Y., Wu, C., Wangpaichitr, M., Jones, P.D., Richman, S.P., et al. (2019) Phase 2 Study of Pembrolizumab and Circulating Biomarkers to Predict Anticancer Response in Advanced, Unresectable Hepatocellular Carcinoma. Cancer, 125, 3603-3614. https://doi.org/10.1002/cncr.32339
|
[32]
|
Mariathasan, S., Turley, S.J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., et al. (2018) TGFβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells. Nature, 554, 544-548.
https://doi.org/10.1038/nature25501
|
[33]
|
Cheuk, A.T., Mufti, G.J. and Guinn, B.A. (2004) Role of 4-1BB:4-1BB Ligand in Cancer Immunotherapy. Cancer Gene Therapy, 11, 215-226. https://doi.org/10.1038/sj.cgt.7700670
|
[34]
|
Reithofer, M., Rosskopf, S., Leitner, J., Battin, C., Bohle, B., Stein-berger, P., et al. (2021) 4-1BB Costimulation Promotes Bystander Activation of Human CD8 T Cells. European Journal of Immunology, 51, 721-733.
|
[35]
|
Heinisch, I.V., Daigle, I., Knöpfli, B. and Simon, H.U. (2000) CD137 Activation Abrogates Granulocyte-Macrophage Colony-Stimulating Factor-Mediated Anti-Apoptosis in Neutrophils. European Journal of Immunology, 30, 3441-3446.
https://doi.org/10.1002/1521-4141(2000012)30:12<3441::AID-IMMU3441>3.0.CO;2-L
|
[36]
|
Kim, H.D., Park, S., Jeong, S., Lee, Y.J., Lee, H., Kim, C.G., et al. (2020) 4-1BB Delineates Distinct Activation Status of Exhausted Tu-mor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Hepatology, 71, 955-971.
https://doi.org/10.1002/hep.30881
|
[37]
|
Michel, J., Langstein, J., Hofstädter, F. and Schwarz, H. (1998) A Soluble form of CD137 (ILA/4-1BB), a Member of the TNF Receptor Family, Is Released by Activated Lymphocytes and Is Detectable in Sera of Patients with Rheumatoid Arthritis. European Journal of Immunology, 28, 290-295.
https://doi.org/10.1002/(SICI)1521-4141(199801)28:01<290::AID-IMMU290>3.0.CO;2-S
|
[38]
|
Vinay, D.S. and Kwon, B.S. (1998) Role of 4-1BB in Immune Responses. Seminars in Immunology, 10, 481-489.
https://doi.org/10.1006/smim.1998.0157
|
[39]
|
Geuijen, C., Tacken, P., Wang, L.C., Klooster, R., van Loo, P.F., Zhou, J., et al. (2021) A Human CD137×PD-L1 Bispecific Antibody Promotes Anti-Tumor Immunity via Con-text-Dependent T Cell Costimulation and Checkpoint Blockade. Nature Communications, 12, Article No. 4445. https://doi.org/10.1038/s41467-021-24767-5
|
[40]
|
Jacquelot, N., Roberti, M.P., Enot, D.P., Rusakiewicz, S., Ternès, N., Jegou, S., et al. (2017) Predictors of Responses to Immune Checkpoint Blockade in Advanced Melanoma. Nature Communications, 8, Article 592.
|
[41]
|
Zhang, W., Gong, C., Peng, X., Bi, X., Sun, Y., Zhou, J., et al. (2022) Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevaci-zumab Biosimilar in Advanced Hepatocellular Carcinoma Patients. Clinical Cancer Research, 28, 3499-3508.
https://doi.org/10.1158/1078-0432.CCR-21-3972
|